# VA Augmentation and Switching Treatments for Improving Depression Outcomes

> **NCT01421342** · PHASE3 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 1522 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Switching: Bupropion-SR
- **DRUG:** Augmenting: Antidepressant + Bupropion-SR
- **DRUG:** Augmenting: Antidepressant + Aripiprazole

## Key facts

- **NCT ID:** NCT01421342
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-08
- **Final completion:** 2016-06
- **Target enrollment:** 1522 (ACTUAL)
- **Last updated:** 2018-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01421342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01421342, "VA Augmentation and Switching Treatments for Improving Depression Outcomes". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01421342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*